Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 497

1.

Real-world outcomes and factors impacting treatment choice in relapsed and/or refractory multiple myeloma (RRMM): a comparison of VRd, KRd, and IRd.

Chari A, Richardson PG, Romanus D, Dimopoulos MA, Sonneveld P, Terpos E, Hajek R, Raju A, Palumbo A, Cain LE, Blazer M, Huang H, Farrelly E, Ailawadhi S.

Expert Rev Hematol. 2020 Mar 9:1-13. doi: 10.1080/17474086.2020.1729734. [Epub ahead of print]

PMID:
32148109
2.

Consolidation with carfilzomib, lenalidomide, and dexamethasone (KRd) following ASCT results in high rates of minimal residual disease negativity and improves bone metabolism, in the absence of bisphosphonates, among newly diagnosed patients with multiple myeloma.

Gavriatopoulou M, Terpos E, Ntanasis-Stathopoulos I, Malandrakis P, Eleutherakis-Papaiakovou E, Papatheodorou A, Kanellias N, Migkou M, Fotiou D, Dialoupi I, Roussou M, Kokkali NA, Kastritis E, Dimopoulos MA.

Blood Cancer J. 2020 Mar 2;10(3):25. doi: 10.1038/s41408-020-0297-2. No abstract available.

3.

CCL3 Signaling in the Tumor Microenvironment.

Ntanasis-Stathopoulos I, Fotiou D, Terpos E.

Adv Exp Med Biol. 2020;1231:13-21. doi: 10.1007/978-3-030-36667-4_2. Review.

PMID:
32060842
4.

Real-world data on incidence, clinical characteristics and outcome of patients with macrofocal multiple myeloma (MFMM) in the era of novel therapies: A study of the Greco-Israeli collaborative myeloma working group.

Katodritou E, Kastritis E, Gatt M, Cohen YC, Avivi I, Pouli A, Lalayianni C, Lavi N, Delimpasis S, Kyrtsonis MC, Michael M, Suriu C, Miri Z, Tzafarti K, Vadikoliou C, Maltezas D, Zikos P, Ganzel C, Vaxman Y, Aviv A, Christoforidou A, Gavriatopoulou M, Shaulov A, Verrou E, Papanota AM, Fakinos G, Gkioka AI, Palaska V, Triantafyllou T, Konstantinidou P, Anagnostopoulos A, Terpos E, Dimopoulos MA.

Am J Hematol. 2020 Feb 12. doi: 10.1002/ajh.25755. [Epub ahead of print]

PMID:
32048329
5.

Low Bone Mineral Density and High Bone Turnover in Patients With Non-Hodgkin's Lymphoma (NHL) Who Receive Frontline Therapy: Results of a Multicenter Prospective Study.

Anargyrou K, Fotiou D, Vassilakopoulos TP, Christoulas D, Makras P, Dimou M, Ntanasis-Stathopoulos I, Masouridou S, Angelopoulou MK, Papatheodorou A, Tsionos K, Panayiotidis P, Dimopoulos MA, Terpos E.

Hemasphere. 2019 Sep 24;3(6):e303. doi: 10.1097/HS9.0000000000000303. eCollection 2019 Dec.

6.

Impact of Minimal Residual Disease Detection by Next-Generation Flow Cytometry in Multiple Myeloma Patients with Sustained Complete Remission after Frontline Therapy.

Terpos E, Kostopoulos IV, Kastritis E, Ntanasis-Stathopoulos I, Migkou M, Rousakis P, Argyriou AT, Kanellias N, Fotiou D, Eleutherakis-Papaiakovou E, Gavriatopoulou M, Ziogas DC, Papanota AM, Spyropoulou-Vlachou M, Trougakos IP, Tsitsilonis OE, Paiva B, Dimopoulos MA.

Hemasphere. 2019 Oct 1;3(6):e300. doi: 10.1097/HS9.0000000000000300. eCollection 2019 Dec.

7.

Antibody therapies for multiple myeloma.

Ntanasis-Stathopoulos I, Gavriatopoulou M, Terpos E.

Expert Opin Biol Ther. 2020 Mar;20(3):295-303. doi: 10.1080/14712598.2020.1717464. Epub 2020 Jan 22.

PMID:
31944131
8.

Multiple Myeloma and Thrombosis: Prophylaxis and Risk Prediction Tools.

Fotiou D, Gavriatopoulou M, Terpos E.

Cancers (Basel). 2020 Jan 13;12(1). pii: E191. doi: 10.3390/cancers12010191. Review.

9.

Impact of last lenalidomide dose, duration, and IMiD-free interval in patients with myeloma treated with pomalidomide/dexamethasone.

Kastritis E, Roussou M, Gavriatopoulou M, Kanellias N, Migkou M, Eleutherakis-Papaiakovou E, Ziogas DC, Fotiou D, Ntanasis-Stathopoulos I, Dialoupi I, Giannouli S, Tsirigotis P, Delimpasi S, Mparmparousi D, Spyropoulou-Vlachou M, Xirokosta A, Terpos E, Dimopoulos MA.

Blood Adv. 2019 Dec 10;3(23):4095-4103. doi: 10.1182/bloodadvances.2019000539.

10.

Multiple myeloma: Role of autologous transplantation.

Ntanasis-Stathopoulos I, Gavriatopoulou M, Kastritis E, Terpos E, Dimopoulos MA.

Cancer Treat Rev. 2020 Jan;82:101929. doi: 10.1016/j.ctrv.2019.101929. Epub 2019 Nov 11. Review.

PMID:
31770695
11.

Emerging Insights Into the Role of the Hippo Pathway in Multiple Myeloma and Associated Bone Disease.

Kyriazoglou A, Ntanasis-Stathopoulos I, Terpos E, Fotiou D, Kastritis E, Dimopoulos MA, Gavriatopoulou M.

Clin Lymphoma Myeloma Leuk. 2020 Feb;20(2):57-62. doi: 10.1016/j.clml.2019.09.620. Epub 2019 Oct 9.

PMID:
31734019
12.

Treatment of Bing-Neel syndrome with first line sequential chemoimmunotherapy: A case report.

Gavriatopoulou M, Ntanasis-Stathopoulos I, Moulopoulos LA, Manaios A, Fotiou D, Eleutherakis-Papaiakovou E, Migkou M, Bourgioti C, Terpos E, Kastritis E, Dimopoulos MA.

Medicine (Baltimore). 2019 Nov;98(44):e17794. doi: 10.1097/MD.0000000000017794.

13.

Elotuzumab in combination with pomalidomide and dexamethasone for the treatment of multiple myeloma.

Eleutherakis-Papaiakovou E, Gavriatopoulou M, Ntanasis-Stathopoulos I, Kastritis E, Terpos E, Dimopoulos MA.

Expert Rev Anticancer Ther. 2019 Nov;19(11):921-928. doi: 10.1080/14737140.2019.1685879. Epub 2019 Nov 4. Review.

PMID:
31679403
14.

Primary treatment of light-chain amyloidosis with bortezomib, lenalidomide, and dexamethasone.

Kastritis E, Dialoupi I, Gavriatopoulou M, Roussou M, Kanellias N, Fotiou D, Ntanasis-Stathopoulos I, Papadopoulou E, Ziogas DC, Stamatelopoulos K, Manios E, Ntalianis A, Eleutherakis-Papaiakovou E, Papanikolaou A, Migkou M, Papanota AM, Gakiopoulou H, Psimenou E, Tselegkidi MI, Tsitsilonis O, Kostopoulos I, Terpos E, Dimopoulos MA.

Blood Adv. 2019 Oct 22;3(20):3002-3009. doi: 10.1182/bloodadvances.2019000147.

15.

Non-lethal proteasome inhibition activates pro-tumorigenic pathways in multiple myeloma cells.

Skorda A, Sklirou AD, Sakellaropoulos T, Gianniou DD, Kastritis E, Terpos E, Tsitsilonis OE, Florea BI, Overkleeft HS, Dimopoulos MA, Alexopoulos LG, Trougakos IP.

J Cell Mol Med. 2019 Dec;23(12):8010-8018. doi: 10.1111/jcmm.14653. Epub 2019 Sep 30.

16.

Screening for Gaucher disease among patients with plasma cell dyscrasias.

Ntanasis-Stathopoulos I, Gavriatopoulou M, Fotiou D, Kanellias N, Migkou M, Eleutherakis-Papaiakovou E, Kastritis E, Dimopoulos MA, Terpos E.

Leuk Lymphoma. 2019 Sep 30:1-3. doi: 10.1080/10428194.2019.1672059. [Epub ahead of print] No abstract available.

PMID:
31566473
17.

Circulating noggin levels following treatment with denosumab or teriparatide in postmenopausal women with low bone mass.

Anastasilakis AD, Polyzos SA, Makras P, Rauner M, Sonnleitner L, Hawa G, Tsourdi E, Yavropoulou MP, Missbichler A, Terpos E.

J Musculoskelet Neuronal Interact. 2019 Sep 1;19(3):253-257.

18.

Reactive Vasodilation Predicts Mortality in Primary Systemic Light-Chain Amyloidosis.

Stamatelopoulos K, Georgiopoulos G, Athanasouli F, Nikolaou PE, Lykka M, Roussou M, Gavriatopoulou M, Laina A, Trakada G, Charakida M, Delialis D, Petropoulos I, Pamboukas C, Manios E, Karakitsou M, Papamichael C, Gatsiou A, Lambrinoudaki I, Terpos E, Stellos K, Andreadou I, Dimopoulos MA, Kastritis E.

Circ Res. 2019 Sep 27;125(8):744-758. doi: 10.1161/CIRCRESAHA.119.314862. Epub 2019 Aug 12.

19.

Monoclonal antibodies against RANKL and sclerostin for myeloma-related bone disease: can they change the standard of care?

Kleber M, Ntanasis-Stathopoulos I, Dimopoulos MA, Terpos E.

Expert Rev Hematol. 2019 Aug;12(8):651-663. doi: 10.1080/17474086.2019.1640115. Epub 2019 Jul 16.

PMID:
31268745
20.

Evaluation of MET T1010I and MET rs40239 single-nucleotide polymorphisms in triple-negative breast cancer: a case-control study.

Kalapanida D, Zagouri F, Gazouli M, Tsiakou A, Zografos E, Dimitrakakis C, Marinopoulos S, Giannos A, Sergentanis TN, Kastritis E, Terpos E, Dimopoulos MA.

Onco Targets Ther. 2019 May 28;12:4195-4202. doi: 10.2147/OTT.S189329. eCollection 2019.

21.

International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders.

Hillengass J, Usmani S, Rajkumar SV, Durie BGM, Mateos MV, Lonial S, Joao C, Anderson KC, García-Sanz R, Riva E, Du J, van de Donk N, Berdeja JG, Terpos E, Zamagni E, Kyle RA, San Miguel J, Goldschmidt H, Giralt S, Kumar S, Raje N, Ludwig H, Ocio E, Schots R, Einsele H, Schjesvold F, Chen WM, Abildgaard N, Lipe BC, Dytfeld D, Wirk BM, Drake M, Cavo M, Lahuerta JJ, Lentzsch S.

Lancet Oncol. 2019 Jun;20(6):e302-e312. doi: 10.1016/S1470-2045(19)30309-2. Review. Erratum in: Lancet Oncol. 2019 Jul;20(7):e346.

PMID:
31162104
22.

Management of bone health in solid tumours: From bisphosphonates to a monoclonal antibody.

von Moos R, Costa L, Gonzalez-Suarez E, Terpos E, Niepel D, Body JJ.

Cancer Treat Rev. 2019 Jun;76:57-67. doi: 10.1016/j.ctrv.2019.05.003. Epub 2019 May 15. Review.

23.

A revised international prognostic score system for Waldenström's macroglobulinemia.

Kastritis E, Morel P, Duhamel A, Gavriatopoulou M, Kyrtsonis MC, Durot E, Symeonidis A, Laribi K, Hatjiharissi E, Ysebaert L, Vassou A, Giannakoulas N, Merlini G, Repousis P, Varettoni M, Michalis E, Hivert B, Michail M, Katodritou E, Terpos E, Leblond V, Dimopoulos MA.

Leukemia. 2019 Nov;33(11):2654-2661. doi: 10.1038/s41375-019-0431-y. Epub 2019 May 22.

PMID:
31118465
25.

Multiple Myeloma: Clinical Updates From the American Society of Hematology Annual Meeting 2018.

Terpos E, Ntanasis-Stathopoulos I; International Myeloma Society.

Clin Lymphoma Myeloma Leuk. 2019 Jul;19(7):e324-e336. doi: 10.1016/j.clml.2019.03.008. Epub 2019 Apr 4. Review.

PMID:
31076371
26.

The Growth Differentiation Factor-15 (GDF-15) levels are increased in patients with compound heterozygous sickle cell and beta-thalassemia (HbS/βthal), correlate with markers of hemolysis, iron burden, coagulation, endothelial dysfunction and pulmonary hypertension.

Larissi K, Politou M, Margeli A, Poziopoulos C, Flevari P, Terpos E, Papassotiriou I, Voskaridou E.

Blood Cells Mol Dis. 2019 Jul;77:137-141. doi: 10.1016/j.bcmd.2019.04.011. Epub 2019 Apr 23.

PMID:
31071550
27.

Activin-A is elevated in patients with thalassemia major and double heterozygous sickle cell/beta-thalassemia and correlates with markers of hemolysis and bone mineral density.

Voskaridou E, Ntanasis-Stathopoulos I, Christoulas D, Dimopoulou M, Komninaka V, Repa K, Papatheodorou A, Terpos E.

Ann Hematol. 2019 Jul;98(7):1583-1592. doi: 10.1007/s00277-019-03695-x. Epub 2019 Apr 30.

PMID:
31041514
28.

A cost-effectiveness analysis of denosumab for the prevention of skeletal-related events in patients with multiple myeloma in four European countries: Austria, Belgium, Greece, and Italy.

Terpos E, Jamotte A, Christodoulopoulou A, Campioni M, Bhowmik D, Kennedy L, Willenbacher W.

J Med Econ. 2019 Aug;22(8):766-776. doi: 10.1080/13696998.2019.1606002. Epub 2019 Apr 29.

PMID:
30969797
29.

Updates on thrombotic events associated with multiple myeloma.

Fotiou D, Gavriatopoulou M, Ntanasis-Stathopoulos I, Migkou M, Dimopoulos MA, Terpos E.

Expert Rev Hematol. 2019 May;12(5):355-365. doi: 10.1080/17474086.2019.1604214. Epub 2019 Apr 14.

PMID:
30957573
30.

Evaluation of regulatory T cells (Tregs) alterations in patients with multiple myeloma treated with bortezomib or lenalidomide plus dexamethasone: correlations with treatment outcome.

Hadjiaggelidou C, Mandala E, Terpos E, Yiannaki E, Markala D, Triantafyllou T, Papatheodorou A, Gkastari V, Verrou E, Papanikolaou A, Konstantinidou P, Katodritou E.

Ann Hematol. 2019 Jun;98(6):1457-1466. doi: 10.1007/s00277-019-03657-3. Epub 2019 Mar 20.

PMID:
30895351
31.

Bone Metabolism Markers in Thalassemia Major-Induced Osteoporosis: Results from a Cross-Sectional Observational Study.

Tsartsalis AN, Lambrou GI, Tsartsalis DN, Papassotiriou I, Vlachou E, Terpos E, Chrousos GP, Kanaka-Gantenbein C, Kattamis A.

Curr Mol Med. 2019;19(5):335-341. doi: 10.2174/1566524019666190314114447.

PMID:
30868952
32.

Pulmonary function abnormalities are common in patients with multiple myeloma and are independently associated with worse outcome.

Trakada G, Kastritis E, Gavriatopoulou M, Velentza L, Fotiou D, Ziogas DC, Panagiotidis I, Eleutherakis-Papaiakovou E, Roussou M, Migkou M, Kanellias N, Ntanasis-Stathopoulos I, Kallianos A, Terpos E, Dimopoulos MA.

Ann Hematol. 2019 Jun;98(6):1427-1434. doi: 10.1007/s00277-019-03641-x. Epub 2019 Mar 5.

PMID:
30834954
33.

Toll-Like Receptor 4 Activation Promotes Multiple Myeloma Cell Growth and Survival Via Suppression of The Endoplasmic Reticulum Stress Factor Chop.

Bagratuni T, Sklirou AD, Kastritis E, Liacos CI, Spilioti C, Eleutherakis-Papaiakovou E, Kanellias N, Gavriatopoulou M, Terpos E, Trougakos IP, Dimopoulos MA.

Sci Rep. 2019 Mar 1;9(1):3245. doi: 10.1038/s41598-019-39672-7.

34.

INSIGHT MM: a large, global, prospective, non-interventional, real-world study of patients with multiple myeloma.

Costello C, Davies FE, Cook G, Vela-Ojeda J, Omel J, Rifkin RM, Berdeja J, Puig N, Usmani SZ, Weisel K, Zonder JA, Terpos E, Spencer A, Leleu X, Boccadoro M, Thompson MA, Romanus D, Stull DM, Hungria V.

Future Oncol. 2019 May;15(13):1411-1428. doi: 10.2217/fon-2019-0013. Epub 2019 Feb 28.

35.

Anti-BCMA antibodies in the future management of multiple myeloma.

Gavriatopoulou M, Ntanasis-Stathopoulos I, Dimopoulos MA, Terpos E.

Expert Rev Anticancer Ther. 2019 Apr;19(4):319-326. doi: 10.1080/14737140.2019.1586539. Epub 2019 Mar 18. Review.

PMID:
30810049
36.

The role of cement augmentation with percutaneous vertebroplasty and balloon kyphoplasty for the treatment of vertebral compression fractures in multiple myeloma: a consensus statement from the International Myeloma Working Group (IMWG).

Kyriakou C, Molloy S, Vrionis F, Alberico R, Bastian L, Zonder JA, Giralt S, Raje N, Kyle RA, Roodman DGD, Dimopoulos MA, Rajkumar SV, Durie BBG, Terpos E.

Blood Cancer J. 2019 Feb 26;9(3):27. doi: 10.1038/s41408-019-0187-7.

37.

Bone marrow biopsy in low-risk monoclonal gammopathy of undetermined significance reveals a novel smoldering multiple myeloma risk group.

Bustoros M, Kastritis E, Sklavenitis-Pistofidis R, Liu CJ, Hornburg K, Kanellias N, Kim G, Liu D, Gavriatopoulou M, Marinac CR, Roussou M, Migkou M, Noonan K, Reyes K, Rivotto B, Neuse CJ, Ziogas DC, Laubach J, Terpos E, Anderson KC, Richardson PG, Ghobrial IM, Dimopoulos MA.

Am J Hematol. 2019 May;94(5):E146-E149. doi: 10.1002/ajh.25441. Epub 2019 Mar 6. No abstract available.

PMID:
30773670
38.

Myeloma bone disease: from biology findings to treatment approaches.

Terpos E, Ntanasis-Stathopoulos I, Dimopoulos MA.

Blood. 2019 Apr 4;133(14):1534-1539. doi: 10.1182/blood-2018-11-852459. Epub 2019 Feb 13. Review.

PMID:
30760454
39.

Development of an Initial Conceptual Model of Multiple Myeloma to Support Clinical and Health Economics Decision Making.

Gonzalez-McQuire S, Dimopoulos MA, Weisel K, Bouwmeester W, Hájek R, Campioni M, Bennison C, Xu W, Pantiri K, Hensen M, Terpos E, Knop S.

MDM Policy Pract. 2019 Jan 17;4(1):2381468318814253. doi: 10.1177/2381468318814253. eCollection 2019 Jan-Jun.

40.

Prevention, monitoring and treatment of cardiovascular adverse events in myeloma patients receiving carfilzomib A consensus paper by the European Myeloma Network and the Italian Society of Arterial Hypertension.

Bringhen S, Milan A, D'Agostino M, Ferri C, Wäsch R, Gay F, Larocca A, Offidani M, Zweegman S, Terpos E, Goldschmidt H, Cavo M, Ludwig H, Driessen C, Auner HW, Caers J, Gramatzki M, Dimopoulos MA, Boccadoro M, Einsele H, Sonneveld P, Engelhardt M.

J Intern Med. 2019 Jul;286(1):63-74. doi: 10.1111/joim.12882. Epub 2019 Apr 8.

41.

The extended 4-year follow-up results of the ELOQUENT-2 trial.

Gavriatopoulou M, Terpos E, Dimopoulos MA.

Oncotarget. 2019 Jan 4;10(2):82-83. doi: 10.18632/oncotarget.26527. eCollection 2019 Jan 4. No abstract available.

42.

Bortezomib retreatment for relapsed and refractory multiple myeloma in real-world clinical practice.

Hulin C, de la Rubia J, Dimopoulos MA, Terpos E, Katodritou E, Hungria V, De Samblanx H, Stoppa AM, Aagesen J, Sargin D, Sioni A, Belch A, Diels J, Olie RA, Robinson D Jr, Potamianou A, van de Velde H, Delforge M.

Health Sci Rep. 2018 Dec 7;2(1):e104. doi: 10.1002/hsr2.104. eCollection 2019 Jan.

43.

Optimizing Immunomodulatory Drug With Proteasome Inhibitor Combinations in Newly Diagnosed Multiple Myeloma.

Ntanasis-Stathopoulos I, Terpos E, Dimopoulos MA.

Cancer J. 2019 Jan/Feb;25(1):2-10. doi: 10.1097/PPO.0000000000000348. Review.

PMID:
30694854
44.

Denosumab effects on serum levels of the bone morphogenetic proteins antagonist noggin in patients with transfusion-dependent thalassemia and osteoporosis.

Voskaridou E, Ntanasis-Stathopoulos I, Christoulas D, Sonnleitner L, Papaefstathiou A, Dimopoulou M, Missbichler A, Kanellias N, Repa K, Papatheodorou A, Peppa M, Hawa G, Terpos E.

Hematology. 2019 Dec;24(1):318-324. doi: 10.1080/16078454.2019.1570617.

PMID:
30665323
45.

Efficacy of lenalidomide as salvage therapy for patients with AL amyloidosis.

Kastritis E, Gavriatopoulou M, Roussou M, Bagratuni T, Migkou M, Fotiou D, Ziogas DC, Kanellias N, Eleutherakis-Papaiakovou E, Dialoupi I, Ntanasis-Stathopoulos I, Spyropoulou-Vlachou M, Psimenou E, Gakiopoulou H, Marinaki S, Papadopoulou E, Ntalianis A, Terpos E, Dimopoulos MA.

Amyloid. 2018 Dec;25(4):234-241. doi: 10.1080/13506129.2018.1540410. Epub 2019 Jan 20.

PMID:
30663408
46.

Evaluation of pre-mir-34a rs72631823 single nucleotide polymorphism in triple negative breast cancer: A case-control study.

Kalapanida D, Zagouri F, Gazouli M, Zografos E, Dimitrakakis C, Marinopoulos S, Giannos A, Sergentanis TN, Kastritis E, Terpos E, Dimopoulos MA.

Oncotarget. 2018 Dec 11;9(97):36906-36913. doi: 10.18632/oncotarget.26385. eCollection 2018 Dec 11.

47.

Effect of induction therapy with lenalidomide, doxorubicin and dexamethasone on bone remodeling and angiogenesis in newly diagnosed multiple myeloma.

Terpos E, Katodritou E, Symeonidis A, Zagouri F, Gerofotis A, Christopoulou G, Gavriatopoulou M, Christoulas D, Ntanasis-Stathopoulos I, Kourakli A, Konstantinidou P, Kastritis E, Dimopoulos MA.

Int J Cancer. 2019 Jul 15;145(2):559-568. doi: 10.1002/ijc.32125. Epub 2019 Jan 22.

PMID:
30650184
48.

Vulnerability variables among octogenerian myeloma patients: a single-center analysis of 110 patients.

Gavriatopoulou M, Fotiou D, Koloventzou U, Roussou M, Migkou M, Ntanasis-Stathopoulos I, Kanellias N, Ziogas DC, Panagiotidis I, Gika D, Eleutherakis-Papaiakovou E, Terpos E, Kastritis E, Dimopoulos MA.

Leuk Lymphoma. 2019 Mar;60(3):619-628. doi: 10.1080/10428194.2018.1509323. Epub 2019 Jan 10.

PMID:
30628505
49.

Consolidation therapy with the combination of bortezomib and lenalidomide (VR) without dexamethasone in multiple myeloma patients after transplant: Effects on survival and bone outcomes in the absence of bisphosphonates.

Terpos E, Kastritis E, Ntanasis-Stathopoulos I, Christoulas D, Papatheodorou A, Eleutherakis-Papaiakovou E, Kanellias N, Fotiou D, Ziogas DC, Migkou M, Roussou M, Trougakos IP, Gavriatopoulou M, Dimopoulos MA.

Am J Hematol. 2019 Apr;94(4):400-407. doi: 10.1002/ajh.25392. Epub 2019 Jan 10.

PMID:
30592079
50.

How I treat elderly patients with plasma cell dyscrasias.

Gavriatopoulou M, Fotiou D, Ntanasis-Stathopoulos I, Kastritis E, Terpos E, Dimopoulos MA.

Aging (Albany NY). 2018 Dec 18;10(12):4248-4268. doi: 10.18632/aging.101707. Review.

Supplemental Content

Loading ...
Support Center